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CASE REPORTS
A case of dual chloroquine 
and halofantrine treatment 
failure in Zimbabwe
SMHARAKURWA
SUMMARY
A case of malaria treatment failure with chloroquine 
and halofantrine is reported. The likely determinants 
and policy considerations are addressed.
INTRODUCTION
Global escalation of Plasmodium falciparum drug re­
sistance continues to complicate treatment and pose a 
major setback for malaria control.1"* Resistance to 
chloroquine, the erstwhile most effective and safe 
drug, has spread to all but a few isolated foci over the 
past few decades.1,4 This has seen the recent develop­
ment and gradual introduction of novel and alternative 
antimalarial compounds such as artemisinine and its 
derivatives, and the phenathrene methanol halofantrine.
Chloroquine still remains the drug of first choice for 
treatment of uncomplicated malaria in Zimbabwe.
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Figure I: Schedule o f  events pre and post treatment (TF, thick film).
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resistant infections, and paucity of a streamlined ser­
vice mechanism to perform sensitivity tests on sus­
pected resistantcases, a few drugs have found their way 
into the market and often into prescription before local 
clinical evaluation. The present case report shows how 
this may be adding new dimensions to the malaria 
problem.
CASE REPORT
An adult male resident of Harare contracted malaria 
while working in an endemic irrigated commercial 
farm area of Mutare district (Burma Valley, ref 32° 
48’E, 18° 35’S), from 27 September to 15 November 
1994. The patient, who was not on prophylactic, suf­
fered a clinical onset upon return to Harare and took a 
full adult course of chloroquine on 19 November 1994 
(Figure I).
Owing to continuing illness despite treatment, on 23 
November 1994 he saw a general practitioner and 
received a prescription of halofantrine (Halfan®), ie a 
total of six tablets of 250mg halofantrine hydrochlo­
ride, taken two six hourly. Clinical improvement even 
after the halofantrine course was only transient, how­
ever, and because of persisting symptoms a further 
course of chloroquine was taken (date unknown), which 
was not completed (a total of eight tablets of 150mg 
chloroquine base were taken), and subsequently, on 12 
December, he revisited the GP. After protracted clini­
cal episodes, amelliorated with analgesics (mostly 
paracetamol), on 3 January 1995 a thick film taken at 
Blair Research Laboratory was positive for Plasmo- , 
dium falciparum, with >2 000 asexual parasites/pl > 
blood prominent gametocytaemia. The patient was 
successfully cured with the sulfadoxine/pyrimethamine 
combination (Fansidar®, given as three tablets start of 
1 500 mg sulfadoxine + 25mg pyrimethamine).
DISCUSSION
Because the patient was not cured prior to sulfadoxine/ 
pyrimethamine treatment, and did not revisit a malaria 
endemic area, this case exhibited dual treatment failure 
to chloroquine and halofantrine. Most probably, the 
infection was chloroquine-resistant, which is hardly 
surprising as numerous cases have been documented in 
various parts of the country.3-8 With halofantrine, how­
ever, failure to cure was likely due to malabsorption. 
Halofantrine is an effective antimalarial compound 
with no evidence of cross resistance to chloroquine.2,9- 
10 Moreover, there has not been resistance selection 
pressure for the phenanthrene methanol, which is new 
in the country. It is known, though, that current tablet 
formulations of this sparingly soluble drug have shown 
evidence of erratic bioavailability in different individu­
als," which has been related to treatment failure.12-14 
WHO recommended that better formulations of the 
drug be developed,2 and indeed studies have recently 
been initiated on a new micronized formulation.14-13
In view of this potential intersubject variation in 
bioavailability it is recommended that local efficacy 
studies be conducted, with special emphasis on in vivo 
cure rates and bioabsorption. If malabsorption rates are 
substantial with wider introduction of the drug, preva­
lent subtherapeutic levels may select for halofantrine 
resistance and may not justify the relative cost of the 
drug. With the advent of drug resistance there is greater 
need for adherence to a rational drug policy tailored to 
the epidemiological situation and to minimising spread 
of drug resistance. The sending of heparinized blood 
specimens from suspect drug resistant cases to a central 
laboratory (eg Blair Research Laboratory) for in vitro 
confirmation needs to be strengthened. It may also be 
a beneficial alternative or complement to review such 
cases on day seven (and where possible day 14) post 
treatment,16-17 whence thick film positivity would indi-
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cate second line therapy, which in Zimbabwe is
sulfadoxine/pyrimethamine.
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